Evidence map›Paper›PMID 24458104›Full record

Trial reportFood & function2014

Acute effects of an oral supplement of (-)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects.

Gabriela Gutiérrez-Salmeán, Pilar Ortiz-Vilchis, Claudia M Vacaseydel, Ivan Rubio-Gayosso, Eduardo Meaney, Francisco Villarreal, Israel Ramírez-Sánchez, Guillermo Ceballos

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Food & function, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04112251 (Effect of Cocoa Flavonols Oral Supplement on Body Composition, Metabolic, Inflammatory and Oxidative Profile in Obese Subject 10 to 16 Years), which is not on this map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04112251 nacompletednot on this mapstarted 2019, after this paper: background citation

Effect of Cocoa Flavonols Oral Supplement on Body Composition, Metabolic, Inflammatory and Oxidative Profile in Obese Subject 10 to 16 Years

TypeinterventionalSponsorNational Polytechnic Institute, MexicoRan2019 to 2020Enrolled104ConditionsChildhood Obesity, Adolescent ObesityArmsCocoa Flavonols Supplement
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Green tea and metabolic syndrome: A 10-year research update review.Iranian journal of basic medical sciences · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Gabriela Gutiérrez-SalmeánLaboratorio de Investigación Integral Cardiometabólica, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n. Casco de Santo Tomás, Miguel Hidalgo. C.P. 11340, Mexico City, Mexico. gceballosr@ipn.mx.
Pilar Ortiz-Vilchis
Claudia M Vacaseydel
Ivan Rubio-Gayosso
Eduardo Meaney
Francisco Villarreal
Israel Ramírez-Sánchez
Guillermo Ceballos
Instituto Politécnico Nacional · MXUniversity of California, San Diego · US

Funding

San Diego EXPORT Comprehensive NCMHD Research CenterP60MD000220 · NIMHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLARREAL, FRANCISCO · 2002 to 2011
$11.0M
Molecular biology and mechanics of the cardiac interstitiumR01HL043617 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLARREAL, FRANCISCO J · 1989 to 2011
$3.5M
Epicatechin and derivatives to preserve muscle structure function in diabetesR01DK098717 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HENRY, ROBERT ROY, VILLARREAL, FRANCISCO J · 2014 to 2017
$1.4M
Effects of Cocoa Flavonols on Myocardial Infarction Size and Post-Injury InjuryR21AT004277 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLARREAL, FRANCISCO J · 2008 to 2009
$479k
Targeting cellular bioenergetics for the prevention and treatment of diabetesR24DK092154 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLARREAL, FRANCISCO J · 2011 to 2011
$459k
NCCIH NIH HHS AT4277NCCIH NIH HHS R21 AT004277NHLBI NIH HHS HL43617NHLBI NIH HHS R01 HL043617NIDDK NIH HHS DK98717NIDDK NIH HHS R24 DK092154NIMHD NIH HHS P60 MD000220NIMHD NIH HHS P60MD001
6 · The paper itself

Abstract

Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (-)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg(-1)). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia.

Indexed as

AdultBlood GlucoseCarbohydrate MetabolismCatechinFatsFemaleHumansHyperglycemiaMaleOverweightTriglyceridesBlood GlucoseCatechinFatsTriglycerides

Identifiers

PMID24458104
PMCPMC3947792
OpenAlexW2167607459

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.